379 Shares in Axon Enterprise, Inc $AXON Bought by Mutual Advisors LLC

Mutual Advisors LLC bought a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON) during the 2nd quarter, Holdings Channel.com reports. The firm bought 379 shares of the biotechnology company’s stock, valued at approximately $314,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ritholtz Wealth Management raised its position in shares of Axon Enterprise by 20.7% during the second quarter. Ritholtz Wealth Management now owns 847 shares of the biotechnology company’s stock worth $701,000 after acquiring an additional 145 shares during the last quarter. Harbour Investments Inc. increased its position in Axon Enterprise by 24.6% during the 2nd quarter. Harbour Investments Inc. now owns 558 shares of the biotechnology company’s stock valued at $462,000 after purchasing an additional 110 shares during the period. Bayforest Capital Ltd bought a new position in Axon Enterprise during the 2nd quarter worth approximately $370,000. Sagespring Wealth Partners LLC raised its holdings in Axon Enterprise by 26.2% during the 2nd quarter. Sagespring Wealth Partners LLC now owns 785 shares of the biotechnology company’s stock worth $650,000 after purchasing an additional 163 shares during the last quarter. Finally, TD Asset Management Inc lifted its position in shares of Axon Enterprise by 1.7% in the 2nd quarter. TD Asset Management Inc now owns 34,655 shares of the biotechnology company’s stock worth $28,692,000 after purchasing an additional 577 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, Director Hadi Partovi bought 1,358 shares of the stock in a transaction that occurred on Wednesday, August 13th. The shares were bought at an average price of $740.00 per share, for a total transaction of $1,004,920.00. Following the acquisition, the director directly owned 237,938 shares of the company’s stock, valued at approximately $176,074,120. The trade was a 0.57% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Joshua Isner sold 15,919 shares of the firm’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the completion of the transaction, the president directly owned 238,379 shares in the company, valued at approximately $177,892,712.54. The trade was a 6.26% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 59,932 shares of company stock valued at $45,115,616. Corporate insiders own 5.70% of the company’s stock.

Axon Enterprise Stock Up 1.9%

Shares of NASDAQ:AXON opened at $683.13 on Tuesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. Axon Enterprise, Inc has a 52-week low of $422.38 and a 52-week high of $885.91. The business’s 50 day simple moving average is $736.73 and its two-hundred day simple moving average is $720.91. The firm has a market cap of $53.63 billion, a P/E ratio of 168.67, a PEG ratio of 26.04 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. During the same period in the prior year, the firm earned $1.20 earnings per share. Axon Enterprise’s revenue for the quarter was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analysts Set New Price Targets

AXON has been the subject of several recent analyst reports. Raymond James Financial reiterated an “outperform” rating and set a $855.00 price objective (up from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Piper Sandler began coverage on Axon Enterprise in a research report on Tuesday, September 23rd. They issued an “overweight” rating and a $893.00 price objective for the company. JMP Securities reissued a “market outperform” rating and issued a $825.00 price objective on shares of Axon Enterprise in a research note on Monday, September 29th. Northland Securities set a $800.00 target price on Axon Enterprise in a research note on Tuesday, August 5th. Finally, UBS Group restated a “neutral” rating and set a $840.00 price target (up from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Fourteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $841.64.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.